Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies
Information source: Hormozgan University of Medical Sciences
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Preeclampsia; Fetal Death; Fetal Membranes, Premature Rupture
Intervention: misoprostol (Drug); dinoprostone (Drug)
Phase: Phase 1/Phase 2
Status: Not yet recruiting
Sponsored by: Hormozgan University of Medical Sciences Official(s) and/or principal investigator(s):
Mitra Ahmad Soltani, Principal Investigator, Affiliation: Hormozgan University of Medical Sciences
Minoo Rajaee Lari, Perinatologist - Obs and Gyn, Study Chair, Affiliation: Department of Obs and Gyn - HUMS
Summary
Hypothesis (H0): Labor duration and obstetric complications are not significantly different
in the three groups (misoprostol-dinoprostone-oxytocin).
Clinical Details
Study design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Term pregnancy
- Singleton
- Vertex
- Bishop score below 6
Exclusion Criteria:
- History of drug reaction
- Medical disease
- IUGR
- Oligohydramnios
- Vaginal bleeding
- Fetal anomaly
- Uterine scar
Locations and Contacts
Shariaty Maternity Hospital, Tehran, Iran, Islamic Republic of
Additional Information
Last updated: May 31, 2007
|
